Karyopharm Therapeutics Inc. (KPTI) Return on equity 2016–2020
Karyopharm Therapeutics Inc. (KPTI) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-388.3%FY2020 · since FY2016: -67.5% → -388.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2020 | -388.3% | +12.7 pp |
| FY2019 | -401.0% | -303.6 pp |
| FY2018 | -97.4% | +2.2 pp |
| FY2017 | -99.6% | -32.1 pp |
| FY2016 | -67.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More KPTI financial trends
KPTI RevenueKPTI Net incomeKPTI Net marginKPTI Gross profitKPTI Gross marginKPTI Operating incomeKPTI Operating marginKPTI Operating cash flowKPTI Free cash flowKPTI Capital expendituresKPTI Stock buybacksKPTI Dividends paidKPTI Total assetsKPTI Total liabilitiesKPTI Shareholders’ equityKPTI overview →